Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc. (HALO)
Filing Type: Form 8-K (Current Report)
Report Date: February 17, 2026
Reporting Period: Fourth quarter ended December 31, 2025
This filing serves as a notification that the company issued a press release on February 17, 2026, reporting its financial results for the fourth quarter of 2025. The press release is attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are located in the attached press release (Exhibit 99.1), which is not included in the input text. Therefore, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes versus the prior comparable period are detailed in this document. The filing solely references the issuance of the quarterly results press release.
Guidance, Outlook, and Risks
This document does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. These items, if present, would be contained within the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q4 2025 revenue and net income figures.
- Verify year-over-year growth rates and margin trends in the full press release.
- Check for any updated full-year 2025 guidance or 2026 outlook provided in the press release.
- Confirm cash position and liquidity details as reported in the full financial results.